Overview

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Status:
Recruiting

Trial end date:
2021-10-25

Target enrollment:

Participant gender:

Summary

To evaluate whether the efficacy of the abiraterone acetate tablets (I) is comparable to that of the ZYTIGA®) by comparing the serum testosterone concentrations on Day 9 and/or Day 10 after oral administration of the two formulations in patients with metastatic castration-resistant prostate cancer (mCRPC).

Phase:

Phase 2

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Abiraterone Acetate